Verona Pharma Plc - Adr (VRNA)

$21.07

-1.41

(-6.27%)

Market is closed - opens 7 PM, 25 Jul 2024

Performance

  • $20.93
    $22.34
    $21.07
    downward going graph

    0.66%

    Downside

    Day's Volatility :6.29%

    Upside

    5.66%

    downward going graph
  • $11.39
    $23.72
    $21.07
    downward going graph

    45.94%

    Downside

    52 Weeks Volatility :51.98%

    Upside

    11.17%

    downward going graph

Returns

PeriodVerona Pharma Plc - AdrSector (Health Care)Index (Russel 2000)
3 Months
47.51%
5.5%
0.0%
6 Months
32.31%
7.2%
0.0%
1 Year
12.4%
9.3%
0.0%
3 Years
290.28%
13.0%
-19.9%

Highlights

Market Capitalization
1.8B
Book Value
$2.78
Earnings Per Share (EPS)
-0.8
PEG Ratio
0.0
Wall Street Target Price
36.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-14.92%
Return On Equity TTM
-25.28%
Revenue TTM
458.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
112.0K
EBITDA
-72.4M
Diluted Eps TTM
-0.8
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.64
EPS Estimate Next Year
-1.13
EPS Estimate Current Quarter
-0.16
EPS Estimate Next Quarter
-0.21

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Verona Pharma Plc - Adr(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 70.86%

Current $21.07
Target $36.00

Technicals Summary

Sell

Neutral

Buy

Verona Pharma Plc - Adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Verona Pharma Plc - Adr
Verona Pharma Plc - Adr
43.28%
32.31%
12.4%
290.28%
297.88%
Moderna, Inc.
Moderna, Inc.
-11.5%
19.92%
-1.43%
-63.9%
737.94%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.78%
11.32%
45.17%
82.69%
236.57%
Novo Nordisk A/s
Novo Nordisk A/s
-6.33%
26.68%
64.47%
198.6%
438.18%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.24%
14.68%
37.33%
146.48%
182.87%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Verona Pharma Plc - Adr
Verona Pharma Plc - Adr
NA
NA
0.0
-1.64
-0.25
-0.15
NA
2.78
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.55
31.55
1.46
44.35
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.95
45.95
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.16
32.16
0.53
17.04
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Verona Pharma Plc - Adr
Verona Pharma Plc - Adr
Buy
$1.8B
297.88%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.9B
737.94%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.9B
236.57%
31.55
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.6B
438.18%
45.95
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.0B
182.87%
32.16
39.46%

Insights on Verona Pharma Plc - Adr

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 64.5% return, outperforming this stock by 52.1%

Institutional Holdings

  • RA Capital Management, LLC

    7.79%
  • NEA Management Company, LLC

    6.30%
  • Wellington Management Company LLP

    4.82%
  • Perceptive Advisors LLC

    4.64%
  • Vivo Capital, LLC

    4.45%
  • Orbimed Advisors, LLC

    4.19%

Company Information

verona pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. we are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (copd) and cystic fibrosis (cf), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. we are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. in addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. verona pharma is listed on the nasdaq global market in the united states under the ticker symbol vrna and on the london stock exchange in the united kin

Organization
Verona Pharma Plc - Adr
Employees
79
CEO
Dr. David S. Zaccardelli Pharm.D.
Industry
Health Technology

FAQs